December 2024

Press Release
Reschedule Meeting, Supplemental Disclosure for Transaction involving the Sale of Assets and Board Update
1.1291550925925926 days ago Dec 20, 2024
RepliCel Life Sciences Reschedules Meeting, Provides Supplemental Disclosure  for Transaction involving the Sale of Assets...
Shareholders that have questions are encouraged to contact Andrew Schutte at info@replicel.com or call (604) 248-8730
16.129155092592594 days ago Dec 05, 2024
Shareholders that have questions are encouraged to contact Andrew Schutte at: info@replicel.com or call  (604)...
Information Circular and Form of Proxy for AGM and Special Meeting 2024 for Download
17.129155092592594 days ago Dec 04, 2024
RepliCel Life Sciences Inc. AGM and Special Shareholder Meeting PDFs Available for Download:RepliCel - Information...
RepliCel Files Information Circular for AGM and Special Shareholders Meeting and Encourages Shareholders to Access Meeting Materials Online
17.129155092592594 days ago Dec 04, 2024
RepliCel Life Sciences Files Management Information Circular  for Annual General and Special Shareholders Meeting and...

by Type

by Topic

by month

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.